The Food and Drug Administration (FDA) approved AstraZeneca's tremelimumab in combination with durvalumab and platinum-based chemotherapy for adult patients with...
FDA
Biliary tract cancer (BTC) is a form of gastrointestinal cancer that occurs in the bile duct, gallbladder, and ampulla of...
The FDA approved the Investigational New Drug application for initiating a Phase 1/2 clinical study of YH001 in combination with...
The FDA has granted breakthrough therapy designation to the ROS1 inhibitor taletrectinib for the treatment of patients with advanced or...
The FDA has granted approval for pemigatinib (Pemazyre) to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) and...
Pediatric patients aged 1 year and above with chronic graft-versus-host disease (cGVHD) can now benefit from ibrutinib following the FDA...
Tisagenlecleucel, sold under the brand name Kymriah was the first gene therapy approved by the FDA on 30 August 2017....
On August 11, 2022, the FDA gave the green light for accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic...
During the last three months, the FDA approved several molecules and indications. In May, the following indications were approved: Fam-trastuzumab...
